{'fraction_non_alphanumeric': 0.02577319587628866, 'fraction_numerical': 0.0029455081001472753, 'mean_word_length': 5.32093023255814, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Anti-angiogenic agents of lung cancer].

Angiogenesis plays an important role in tumor growth; therefore, inhibition of angiogenesis is considered a promising treatment strategy. Many signaling pathways, such as the vascular endothelial growth factor(VEGF)pathway, the Notch pathway, and the integrin pathway, are associated with each other in a complex manner; the VEGF signaling pathway plays a central role in angiogenesis. Bevacizumab is a humanized monoclonal antibody that specifically targets VEGF-A. Two large phase III trials, ECOG4599 and the AVAiL study, showed that bevacizumab combined with chemotherapy improves the outcome of patients with nonsquamous non-small cell lung cancer. Based on these results, bevacizumab is currently the only anti-angiogenic agent approved as the first-line of treatment for advanced nonsquamous non-small cell lung cancer in Japan. Many anti-angiogenic agents are currently in clinical development for the treatment of non-small cell lung cancer. These agents show antitumor activity by binding to a ligand and inhibiting the activation of receptor tyrosine kinases. However, bevacizumab is currently the only agent that extends overall survival. This review mainly discusses the results of a recent phase III trial with bevacizumab. We also discuss the results of a recent trial with new anti-angiogenic agents.